Alessandro Marra

2.0k total citations
42 papers, 1.5k citations indexed

About

Alessandro Marra is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Alessandro Marra has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Alessandro Marra's work include Lung Cancer Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (7 papers) and Pleural and Pulmonary Diseases (6 papers). Alessandro Marra is often cited by papers focused on Lung Cancer Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (7 papers) and Pleural and Pulmonary Diseases (6 papers). Alessandro Marra collaborates with scholars based in Germany, Italy and United States. Alessandro Marra's co-authors include Ludger Hillejan, Wolfgang E. Berdel, Carsten Müller‐Tidow, L. H. Schmidt, Rainer Wiewrodt, Etmar Bulk, Antje Hascher, Tilmann Spieker, Steffen Koschmieder and Julia Humberg and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Oncogene.

In The Last Decade

Alessandro Marra

39 papers receiving 1.5k citations

Peers

Alessandro Marra
Jian Zhou China
Tian Du China
Stefan David United States
Nadire Duru United States
L. M. Ellis United States
Xin Yin China
Jian Zhou China
Alessandro Marra
Citations per year, relative to Alessandro Marra Alessandro Marra (= 1×) peers Jian Zhou

Countries citing papers authored by Alessandro Marra

Since Specialization
Citations

This map shows the geographic impact of Alessandro Marra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Marra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Marra more than expected).

Fields of papers citing papers by Alessandro Marra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Marra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Marra. The network helps show where Alessandro Marra may publish in the future.

Co-authorship network of co-authors of Alessandro Marra

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Marra. A scholar is included among the top collaborators of Alessandro Marra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Marra. Alessandro Marra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cui, Chunhong, Yi Liu, Dennis Gerloff, et al.. (2020). NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. Oncogene. 40(5). 909–921. 39 indexed citations
2.
Schulze, Arik Bernard, Georg Evers, Dennis Görlich, et al.. (2020). Tumor infiltrating T cells influence prognosis in stage I–III non-small cell lung cancer. Journal of Thoracic Disease. 12(5). 1824–1842. 40 indexed citations
3.
Schulze, Arik Bernard, L. H. Schmidt, Birthe Heitkötter, et al.. (2019). Prognostic impact of CD34 and SMA in cancer‐associated fibroblasts in stage I–III NSCLC. Thoracic Cancer. 11(1). 120–129. 23 indexed citations
4.
Mikesch, Jan‐Henrik, Wolfgang Hartmann, L. H. Schmidt, et al.. (2018). Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer. European Respiratory Journal. 52(1). 1701637–1701637. 8 indexed citations
5.
Schmidt, L. H., Birthe Heitkötter, Arik Bernard Schulze, et al.. (2017). Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. PLoS ONE. 12(10). e0186280–e0186280. 53 indexed citations
6.
Schmidt, L. H., Caroline Brand, Christoph Schliemann, et al.. (2017). Potential therapeutic impact of CD13 expression in non-small cell lung cancer. PLoS ONE. 12(6). e0177146–e0177146. 20 indexed citations
7.
Schmidt, L. H., Christoph Schliemann, Arik Bernard Schulze, et al.. (2015). Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC. Lung Cancer. 92. 8–14. 3 indexed citations
8.
Schmidt, L. H., Andreas Kümmel, Dennis Görlich, et al.. (2015). PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS ONE. 10(8). e0136023–e0136023. 197 indexed citations
9.
Schmidt, L. H., Dennis Görlich, Tilmann Spieker, et al.. (2014). Prognostic Impact of Bcl-2 Depends on Tumor Histology and Expression of MALAT-1 lncRNA in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(9). 1294–1304. 55 indexed citations
10.
Cusumano, Giacomo, Alessandro Marra, Filippo Lococo, et al.. (2014). Is Sleeve Lobectomy Comparable in Terms of Short- and Long-Term Results With Pneumonectomy After Induction Therapy? A Multicenter Analysis. The Annals of Thoracic Surgery. 98(3). 975–983. 20 indexed citations
11.
Schmidt, L. H., Tilmann Spieker, Steffen Koschmieder, et al.. (2011). The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth. Journal of Thoracic Oncology. 6(12). 1984–1992. 464 indexed citations
12.
Yu, Jun, Etmar Bulk, Ping Ji, et al.. (2010). The EPHB6 Receptor Tyrosine Kinase Is a Metastasis Suppressor That Is Frequently Silenced by Promoter DNA Hypermethylation in Non–Small Cell Lung Cancer. Clinical Cancer Research. 16(8). 2275–2283. 69 indexed citations
13.
Marra, Alessandro, et al.. (2008). Remediastinoscopy in restaging of lung cancer after induction therapy. Journal of Thoracic and Cardiovascular Surgery. 135(4). 843–849. 46 indexed citations
14.
Silvestri, Barbara, Elena Bandieri, Salvatore Del Prete, et al.. (2008). Oxycodone Controlled-Release as??First-Choice Therapy for Moderate-to-Severe Cancer Pain in??Italian Patients. Clinical Drug Investigation. 28(7). 399–407. 22 indexed citations
15.
Kemming, Dirk, U Vogt, Nicola Tidow, et al.. (2006). Whole Genome Expression Analysis for Biologic Rational Pathway Modeling. Molecular Diagnosis & Therapy. 10(5). 271–280. 8 indexed citations
16.
Marra, Alessandro, Wilfried Eberhardt, Christoph Pöttgen, et al.. (2006). Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour. European Respiratory Journal. 29(1). 117–126. 46 indexed citations
18.
Marra, Alessandro, et al.. (2003). Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis. Journal of Thoracic and Cardiovascular Surgery. 125(3). 543–553. 59 indexed citations
19.
Ciaparrone, Marco, Daniela Terribile, Giuseppe Curigliano, et al.. (1998). P-170 Glycoprotein (MDR) and p53 Expression in Breast Cancer. The Breast Journal. 4(4). 270–276. 2 indexed citations
20.
Masetti, Riccardo, Armando Antinori, Daniela Terribile, et al.. (1996). Breast Cancer in Women 70 Years of Age or Older. Journal of the American Geriatrics Society. 44(4). 390–393. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026